This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Inotek takes in $18mm through sale of preferred shares; closes financing at $23.6mm
09 Oct 2013
Inotek Pharmaceuticals Corp. (ophthalmic therapeutics) has raised $18mm through the sale of Series D preferred shares. New backer Devon Park Bioventures led and was joined by current shareholders Rho Ventures, Care Capital, Pitango Venture Capital, MedImmune Ventures, and Bio*One Capital. Funds will be used to bring INO8875 through Phase II for glaucoma.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?